Therapeutic product registration could be jeopardised by omitting to disclose a pertinent patent, regardless of whether the omission was wilful

Pursuant to the Health Products (Therapeutic Products) Regulations ("HPR"), applicants for registration of a therapeutic product with the Health Sciences Authority ("HSA") in Singapore must declare whether "a patent is in force in respect of the therapeutic product" ("pertinent patent"). This requirement is part of the patent linkage system in Singapore, which ensures that no therapeutic product would be approved before the expiration of the pertinent patent, except with the consent of the owner of the pertinent patent.

In the recent decision of Millennium Pharmaceuticals, Inc, vs Zyfas Medical Co [2020] SGHC 28, the High Court granted a declaration that Zyfas had omitted to disclose matter that is material to its application for the registration of a therapeutic product, even though Zyfas'…

Full article available on PatentHub

Latest insights

More Insights
Energy and Utilities 500x333

Current European plans to promote hydrogen technologies: The Net Zero Industry Act

Apr 25 2024

Read More
Generative AI

Use of AI within the energy sector – Ofgem’s proposals and call for input

Apr 25 2024

Read More
Competition and EU

Competitive Edge newsletter - Special edition on Investigations - April 2024

Apr 25 2024

Read More